Company: PRTA
Filing Date: 2025-05-08
Form Type: 10-Q
Source: 0001559053-25-000023
Chunk: 22

Company: PROTHENA CORP PUBLIC LTD CO
Filing Date: 2025-05-08
Form: 10-Q
Item: Part I, Item 1
Chunk 22
---
2020 EIIP, and 2012 LTIP expire no later than ten years grant.

In May 2024, the Company’s shareholders approved an amendment to the 2018 LTIP to increase the number of ordinary shares available for issuance under the 2018 LTIP by 2,000,000 16,620,433 Upon adoption of the 2018 LTIP, no new awards are permitted under the 2012 LTIP.

As ofMarch 31, 2025, the number of ordinary shares authorized under the 2020 EIIP was1,485,000 and341,584 ordinary shares remained available for future awards under the 2020 EIIP. The Company’s Board of Directors has adopted a series of amendments to increase the ordinary shares available for issuance under the 2020 EIIP and it reserves the right to both amend the 2020 EIIP to increase the number of ordinary shares available and make additional awards to key new hires.

The Company’s option awards generally vest over four years two three years As ofMarch 31, 2025,2,064,131 ordinary shares remained available for grant under the Company’s equity incentive plans.

Share-based Compensation Expense

Share-based compensation expense recorded in these Condensed Consolidated Financial Statements was based on awards granted under the 2012 LTIP, the 2018 LTIP, and the 2020 EIIP. The estimated forfeiture rate as of March 31, 2025 was 7

T he amount of unearned share-based compensation related to unvested stock options atMarch 31, 2025, is$ 82.8. The weighted-average period over which this unearned share-based compensation is expected to be recognized is2.95 years.

The following table summarizes share-based compensation expense for the periods presented (in thousands):

                                              Three Months Ended                                    
                                              March 31,                                             
                                              2025                                2024              
 ────────────────────────────────────────────────────────────────────────────────────────────────────
  Research and development                    $                        4,845      $          5,455  
  General and administrative                                           6,104                 6,928  
  Total share-based compensation expense      $                       10,949      $         12,383  

The Company recognized tax benefits from share-based awards of $ 2.0 2.1

The fair value of the options granted to employees and non-employee directors during the three months ended March 31, 202